Skip to main content
Clinical Trials/NCT05164263
NCT05164263
Recruiting
Phase 4

Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus

Getz Pharma6 sites in 5 countries2,000 target enrollmentApril 1, 2021

Overview

Phase
Phase 4
Intervention
Empagliflozin
Conditions
Type II Diabetes Mellitus
Sponsor
Getz Pharma
Enrollment
2000
Locations
6
Primary Endpoint
SAFETY and TOLERABILITY Outcomes
Status
Recruiting
Last Updated
3 months ago

Overview

Brief Summary

Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.

Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.

Sample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).

Follow up visits: After recruitment, patient is supposed to have three visits for follow-ups.

Visit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.

LABORATORY TESTING:

Reputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R/E. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.

Where in Urine Routine Examination (Urine R/E), we consider as follows:

  • Visual Examination:

    • Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.
    • Urine clarity: Clear, slightly Cloudy, cloudy or turbidity
  • Chemical Examination:

    • Specific gravity
    • pH
    • Bilirubin
    • Urobilinogen
    • Protein
    • Ketone
    • Leukocyte Esterase
  • Microscopic Examination:

    • Red Blood Cells:
    • Epithelial Cells:
    • Amorphous:
    • Pus Cells
    • Bacteria
    • Yeast
    • Casts
    • Crystals

Where in Renal Function Test (RFT), we consider as follows:

  • Blood Urea Nitrogen (BUN): mg/dL
  • Serum Creatinine: mg/dL
  • Estimated Glomerular Filtration Rate (eGFR): mL/min/1.73 m2
Registry
clinicaltrials.gov
Start Date
April 1, 2021
End Date
August 31, 2027
Last Updated
3 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Getz Pharma
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL/min/1.73m2.

Exclusion Criteria

  • Type 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and/or hepatic dysfunctions, where RFT and Urine R/E is abnormal, Diabetic Ketoacidosis and/or hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.

Arms & Interventions

Empagliflozin naive uncontrolled T2DM on oral anti-diabetics & lifestyle modifications for 3 months

Type 2 diabetic males \& females between 18-65 years. * HbA1c: 7.0% - 10% * eGFR ˃60 mL/min/1.73m2. * Patient who will give informed consent

Intervention: Empagliflozin

Outcomes

Primary Outcomes

SAFETY and TOLERABILITY Outcomes

Time Frame: 6 months

Frequency of adverse events, serious adverse events during the course of study follow-up. Percentage of patients who tolerate empagliflozin.

Secondary Outcomes

  • Efficacy outcomes(6 months)

Study Sites (6)

Loading locations...

Similar Trials